as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 19 Nov 2026
₹517.05
Change
+0.65 (0.13%)
Open
₹516.4
Prev. Close
₹516.4
Day High
₹523.8
Day Low
₹508.45
Volume Analysis
Traded
24,758
Delivered
15,473
Delivery %
62.5%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Strong return on equity (20.0%)
Weaknesses (1)
- •Promoter holding is falling
Opportunities (2)
- •Strong 3-year EPS growth (26.7%)
- •FII holding has been rising
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹539.76 | ₹531.78 | ₹524.41 | ₹516.43 | ₹509.06 | ₹501.08 | ₹493.71 |
| Fibonacci | ₹531.78 | ₹525.92 | ₹522.29 | ₹516.43 | ₹510.57 | ₹506.94 | ₹501.08 |
| Camarilla | ₹521.27 | ₹519.86 | ₹518.46 | ₹516.43 | ₹515.64 | ₹514.24 | ₹512.83 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
-22.5%
1 Week
+1.62%
1 Month
+4.38%
3 Months
-3.6%
6 Months
-7.21%
1 Year
-26.23%
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹76.82
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
19.13%
Net margin 11.86% × asset turnover 1.26x × equity multiplier 1.28x
Company Overview
Sector
Healthcare
Market Cap
₹1,461 Cr
P/E (TTM)
71.7
ROE
20.0%
Book Value
₹37.2
Face Value
₹1.0
Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.
TopFund Analysis
Amrutajan Health Ltd lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Financial Strength (100/100), while Valuation (4/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (20.0%); promoter holding is falling. Strong 3-year EPS growth (26.7%).
TopFund Score — Fundamentals Quality
60/100 — AverageData confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 19 Nov 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- +Company is almost debt free.
- +Company has been maintaining a healthy dividend payout of 33.0%
- −Stock is trading at 13.6 times its book value
- −The company has delivered a poor sales growth of 11.8% over past five years.
- −Promoter holding has decreased over last 3 years: -4.07%
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Record date fixed as 7 November 2026 for 1st interim dividend FY2026-27.
CRISIL independently rated Amrutanjan Health Care ESG as 'Adequate' with score 60.
Source: BSE regulatory filings, via Screener.in.
Profit & Loss (Yearly)
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 67 | 69 | 71 | 87 | 86 | 101 | 136 | 131 | 134 | 158 | 177 |
| Expenses + | 53 | 53 | 60 | 182 | 76 | 88 | 118 | 113 | 112 | 134 | 145 |
| Operating Profit | 13 | 16 | 11 | -95 | 10 | 13 | 18 | 17 | 22 | 24 | 31 |
| OPM % | 20.0% | 23.0% | 16.0% | -109.0% | 12.0% | 13.0% | 13.0% | 13.0% | 16.0% | 15.0% | 18.0% |
| Other Income + | 1 | -2 | 0 | 220 | 10 | 5 | 4 | 4 | 3 | 4 | 5 |
| Interest | 1 | 1 | 1 | 0 | 0 | 1 | 3 | 2 | 2 | 1 | 0 |
| Depreciation | 3 | 2 | 2 | 2 | 1 | 2 | 3 | 4 | 4 | 3 | 3 |
| Profit before tax | 11 | 11 | 9 | 123 | 19 | 15 | 16 | 15 | 19 | 24 | 33 |
| Tax % | 45.0% | 46.0% | 42.0% | 25.0% | 38.0% | 34.0% | 39.0% | 35.0% | 36.0% | 38.0% | 37.0% |
| Net Profit + | 6 | 6 | 5 | 92 | 11 | 10 | 10 | 10 | 12 | 15 | 21 |
| EPS in Rs | — | — | — | 30 | — | — | 3 | 3 | 4 | 5 | 7 |
| Dividend Payout % | 22.0% | 32.0% | 45.0% | 19.0% | 40.0% | 45.0% | 45.0% | 43.0% | 38.0% | 34.0% | 27.0% |
| Sales growth | — | 3 | 3 | 22 | -1 | 17 | 35 | -4 | 3 | 17 | 12 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 15 | 20 | 23 | 90 | 94 | 98 | 74 | 79 | 86 | 92 | 106 |
| Borrowings + | 6 | 8 | 8 | 1 | 1 | 30 | 22 | 15 | 8 | 2 | 2 |
| Other Liabilities + | 13 | 10 | 14 | 17 | 20 | 26 | 25 | 27 | 23 | 26 | 29 |
| Total Liabilities | 37 | 41 | 48 | 111 | 118 | 157 | 124 | 124 | 120 | 124 | 140 |
| Fixed Assets + | 16 | 13 | 20 | 16 | 16 | 52 | 33 | 30 | 27 | 24 | 29 |
| CWIP | 0 | 3 | 3 | 2 | 7 | 0 | 1 | 1 | 1 | 4 | 1 |
| Investments | 0 | 0 | 0 | 0 | 46 | 42 | 29 | 25 | 9 | 9 | 9 |
| Other Assets + | 21 | 26 | 25 | 92 | 50 | 62 | 62 | 69 | 83 | 87 | 102 |
| Total Assets | 37 | 41 | 48 | 111 | 118 | 157 | 124 | 124 | 120 | 124 | 140 |
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 10 | 11 | 5 | 6 | 11 | 6 | 4 | 9 | 17 | 18 | 21 |
| Cash from Investing Activity + | 3 | -4 | -8 | 89 | -47 | -29 | 14 | 13 | 16 | -5 | 4 |
| Cash from Financing Activity + | -12 | -1 | -2 | -30 | -8 | 20 | -27 | -14 | -14 | -12 | -13 |
| Net Cash Flow | 1 | 6 | -5 | 65 | -43 | -4 | -9 | 8 | 20 | 1 | 12 |
| Free Cash Flow | 12 | 7 | -3 | 89 | 6 | -5 | 0 | 8 | 17 | 13 | 19 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 103 | 116 | 61 | -13 | 195 | 79 | 48 | 81 | 114 | 117 | 103 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 0.18% | 0.07% | 0.07% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% | 0.04% |
| Public | 41.19% | 40.66% | 40.47% | 40.5% | 40.01% | 39.75% | 38.34% | 38.16% | 38.18% | 38.61% | 38.72% | 43.08% |
| Promoters | 50.59% | 50.59% | 50.58% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% |
| FII | 0.8% | 1.38% | 1.55% | 2.34% | 2.3% | 2.3% | 2.41% | 2.38% | 2.27% | 2.17% | 2.44% | 3.47% |
| DII | 7.24% | 7.29% | 7.32% | 10.6% | 11.13% | 11.41% | 12.7% | 12.9% | 13.0% | 12.66% | 12.29% | 6.9% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Amrutajan Health Ltd (this stock) | 1,461 | 71.7 | 13.58 | 20.0% |
| Jagsonpal Pharmaceuticals | 1,402 | — | 5.82 | — |
| Bharat Parenterals Ltd. | 1,522 | 1227.0 | 4.59 | -2.54% |
| Fermenta Biotech Ltd. | 1,367 | 29.4 | 3.27 | 17.3% |
| Anlon Healthcare Limited | 1,348 | 37.8 | 5.25 | 18.4% |
| Shalby Limited | 1,317 | 33.6 | 1.29 | 2.45% |
| Kopran Ltd | 1,281 | 32.6 | 2.44 | 4.91% |
Which Mutual Funds Hold Amrutajan Health Ltd?
Frequently Asked Questions about Amrutajan Health Ltd
Amrutajan Health Ltd (AMRUTANJAN) closed at ₹517.05 on NSE on 19 November 2026, up 0.65 (0.13%) from the previous close.
Amrutajan Health Ltd trades on the NSE (National Stock Exchange of India) under the symbol AMRUTANJAN.
Amrutajan Health Ltd has a trailing twelve-month P/E (price-to-earnings) ratio of 71.7.
Amrutajan Health Ltd has a dividend yield of 0.97%.
Amrutajan Health Ltd's 52-week high is ₹715.0 and its 52-week low is ₹476.0.
Amrutajan Health Ltd has a market capitalisation of ₹1,461 crore.
Amrutajan Health Ltd has a TopFund Quality Score of 60/100 (Average), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Amrutajan Health Ltd?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.